Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced the next phase of development for its withZeta.ai platform, including planned launches of ZetaSwarm, an autonomous multi-agent AI research system, and ZetaOmics, a computational biology and multi-omic analytics toolkit. The company also introduced new enterprise-grade capabilities designed to support institutional oncology research and drug discovery workflows.
According to the announcement, withZeta.ai is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. The platform serves as a multi-agentic AI co-scientist, leveraging artificial intelligence and machine learning to accelerate cancer therapy development.
Lantern Pharma operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. The company’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The expansion of withZeta.ai with ZetaSwarm and ZetaOmics is expected to enhance the platform’s ability to analyze complex biological data, potentially improving the efficiency of drug discovery and development. For industry leaders, this development signals a growing trend toward integrating multi-agent AI systems in biomedical research, which could reduce the time and cost associated with bringing new cancer therapies to market.
For more information on Lantern Pharma’s latest news and updates, visit the company’s newsroom at https://ibn.fm/LTRN. The full press release is available at https://ibn.fm/YpA7NA.
